Swedish Orphan Biovitrum AB (publ)
LSE:0MTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Swedish Orphan Biovitrum AB (publ)
LSE:0MTD
|
SE |
|
G
|
Gajah Tunggal Tbk PT
XBER:GH8
|
ID |
|
Lion Copper and Gold Corp
OTC:LCGMF
|
CA |
|
Crane NXT Co
F:P8Q
|
US |
|
ActiveOps PLC
F:95D
|
UK |
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
US |
|
T
|
thyssenkrupp AG
XBER:TKA
|
DE |
|
Atlas Salt Inc
XTSX:SALT
|
CA |
|
D
|
Deutsche Lufthansa AG
XHAM:LHA
|
DE |
|
Newgen Software Technologies Ltd
BSE:540900
|
IN |
Wall St Price Targets
0MTD Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for 0MTD is 466.06 SEK with a low forecast of 310.8 SEK and a high forecast of 555.99 SEK.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0MTD's stock price target?
Price Target
466.06
SEK
According to Wall Street analysts, the average 1-year price target for 0MTD is 466.06 SEK with a low forecast of 310.8 SEK and a high forecast of 555.99 SEK.
What is the Revenue forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Net Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
50%
The compound annual growth rate for Net Income over the next 8 years is 50%.
